Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine VEE IA/B V3526 in VEE-Naive Healthy Volunteers After Single Dose Subcutaneous Administration
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Venezuelan Equine Encephalitis
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company
- Locations
- 1
- Primary Endpoint
- Incidence and character of adverse events considered related to the VEE IA/B V3526 vaccine
- Status
- Withdrawn
- Last Updated
- 10 years ago
Overview
Brief Summary
This study is being done to determine the safety and tolerability of a new investigational vaccine referred to as VEE IA/B V3526, which may induce production of specific antibodies in vaccinated humans, and may protect them against infection with the Venezuelan Equine Encephalitis (VEE) Virus.
Detailed Description
Safety Objectives: 1) To determine preliminary safety, reactogenicity, and tolerability of VEE IA/B V3526 in VEE-naïve healthy volunteers after single dose subcutaneous (SC) administration; 2) To evaluate virological safety by assessing serum viremia and viral shedding in nose and throat. Immunogenicity Objectives: 1) To assess the humoral immune response (plaque reduction neutralizing antibody titer (PRNT)) against VEE subtype IA/B after SC administration of different dose-levels of the VEE IA/B V3526 vaccine candidate; 2) To assess duration of immune response over six months after the VEE IA/B V3526 vaccination based on PRNT; and 3) To identify two suitable VEE IA/B V3526 vaccine dose-levels for future administration in dose optimization and expanded safety studies. Exploratory Objectives: 1) To collect and store serum for future development of immunogenicity assays (e.g., ELISA) against multiple VEE subtypes IA/B, IE, IIIA, and other possible subtypes; 2) To collect and store serum for future use in the development of a passive transfer challenge model; 3) Collect VEE IA/B V3526 positive serum (Positive Control Serum) at the Day 21 visit.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The volunteer is a male or female between 18 and 40 years of age (inclusive).
- •The volunteer is able and willing to comply with the protocol procedures: 2-week 15 nights/ (14-day) in-patient stay and availability for follow-up visits for six months post vaccination.
- •The volunteer is in good health, as determined by the Investigator following a complete medical history and physical examination, and the volunteer has had no clinically significant illness by medical history or exam (e.g., asthma, hypertension) or requiring hospitalization within the six months before vaccination in this study.
- •The volunteer has the following laboratory parameters within normal range: \*total WBC, \*hemoglobin, \*platelets, \*LFT (liver function tests (AST, ALT, ALP, bilirubin) and \*negative for proteinuria. Other laboratory parameters must be within 10% of the upper or lower limits of the normal range of the Northwest Kinetics clinical laboratory and not clinically significant as assessed by the Investigator and/or Sponsor Medical Monitor.
- •Female volunteers must not be pregnant or nursing, or must be of non-childbearing potential (e.g., surgically sterilized or postmenopausal). If volunteers are women of childbearing potential (WCBP), they must verbalize use of an acceptable method of contraception (i.e., hormonal contraception (injectable or oral) or intrauterine device) or abstinence for at least 30 days before and through 180 days after vaccination.
- •The volunteer agrees not to donate blood for at least six months after vaccination.
- •The volunteer has successfully completed the Test of Understanding for the protocol (answered 90% questions correctly), has signed an ICF (inclusive of the HIPAA authorization).
- •The volunteer agrees to have his/her blood samples collected and stored for future investigations related to VEE vaccine development (e.g., assay development) and future VEE-related research studies.
- •The volunteer has been provided Northwest Kinetics Site Subject Instructions for participation and agrees with the Northwest Kinetics Site Subject Instructions.
Exclusion Criteria
- •History of exposure to VEE, WEE (Western Equine Encephalitis), EEE (Eastern Equine Encephalitis), and/or CHIK (Chikungunya) with or without serological evidence (PRN).
- •History of allergic reaction to human serum albumin (HSA) or other vaccine components (i.e., DMEM), or history of anaphylaxis or serious adverse reactions to other vaccines.
- •History of seizure disorder or history of encephalitic process with sequelae.
- •Frequent or severe headaches of any etiology.
- •Chronic, severe, or recurrent joint pain or arthritis of any etiology.
- •History of diabetes in first degree relatives.
- •History of gestational diabetes.
- •Abnormal fasting blood glucose.
- •Current use of antiviral and other systemic immunomodulatory pharmacotherapy. Use of immunosuppressive agents or corticosteroids (i.e., systemic total dose of 20 mg/day or 2 mg/kg or 20 mg/day, "burst" therapy, intra-nasally administered, or inhaled steroids within the 3 months prior to the study).
- •Currently enrolled in an investigational protocol or has participated in any clinical trial using an investigational product within the last month.
Outcomes
Primary Outcomes
Incidence and character of adverse events considered related to the VEE IA/B V3526 vaccine
Level and duration of serum viremia and viral shedding in nose and/or throat
Secondary Outcomes
- Store samples collected for the future development of the passive transfer challenge model
- Store VEE IA/B V3526 Positive Control Serum to be used in future studies
- Store samples collected for future use in the development of immunogenicity assays against multiple VEE subtypes IA/B, IE, IIIA, and other possible subtypes